Notably, when we focused the analysis on receptor-positive patients, the frequency of total CD7+CD56+ NK cells exhibiting the tumor markers MUC1 and HER2 appeared to be increased (Figure 5D). The gene discussed is ERBB2; the disease is neoplasm.